SCHEMBL4965612

SCHEMBL4965612

CC(C)(C)OC(=O)NC1CCN(c2ncnc3cc(F)ccc23)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.49
PDE10A Q9Y233 2/20 0.48
KDM4D Q6B0I6 4/20 0.44
SYK P43405 1/20 0.43
PAK1 Q13153 1/20 0.43
ITGB2 P05107 1/20 0.43
ICAM1 P05362 1/20 0.43
ITGAL P20701 1/20 0.43
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
ACACB O00763 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
SIRT3 Q9NTG7 1/20 0.43
PRKDC P78527 1/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
CCRL2 O00421 1/20 0.41
PIM1 P11309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4966180 0.94 PAK1 (0.49) MAP4K4PDE10APAK1CKS1BSKP1
SCHEMBL29647989 0.89 MAP4K4 (0.54) MAP4K4PDE10AKDM4DITGB2ICAM1
SCHEMBL24704639 0.89 MAP4K4 (0.54) MAP4K4PDE10AKDM4DITGB2ICAM1
SCHEMBL29648103 0.85 DRD2 (0.47) MAP4K4PDE10AKDM4DCKS1BSKP1
SCHEMBL4966752 0.83 ENPP1 (0.56) PDE10A
SCHEMBL24704627 0.83 MAP4K4 (0.45) MAP4K4PDE10ACKS1BSKP1SKP2
SCHEMBL29647979 0.83 MAP4K4 (0.45) MAP4K4PDE10ACKS1BSKP1SKP2
SCHEMBL4192113 0.80 MAP4K4 (0.51) MAP4K4PDE10AITGB2ICAM1ITGAL
SCHEMBL2794592 0.80 LMNA (0.55) MAP4K4PDE10AKDM4DPAK1CKS1B
SCHEMBL30945062 0.80 LMNA (0.55) MAP4K4PDE10AKDM4DPAK1CKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899319-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-19 EP disclosed
EP-1893206-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-05 EP disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-01-04 US disclosed
WO-2006135649-A2 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
WO-2006135636-A2 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-12-21 WO disclosed
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281771-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, CDC42BPG, PRKCQ MAP4K4 507/4885PDE10A 4119/4885KDM4D 3221/4885
US-20070004763-A1 AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS FLT3, BMX, ABL1 MAP4K4 276/4885PDE10A 2325/4885KDM4D 1387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.